公开(公告)号：EP2097097B1

公开(公告)日：2018-05-30

申请号：EP07854887.2

申请日：2007-11-30

申请人： E. R. Squibb & Sons, L.L.C.

发明人： KING, David John ,  WITTE, Alison ,  LEBLANC, Heidi N. ,  THEOLIS, Richard ,  MASOOD, Asna ,  YAMANAKA, Mark ,  ZENS, Kyra D. ,  DWIGGINS, Sara R. ,  SPROUL, Tim ,  RAO-NAIK, Chetana ,  PASSMORE, David ,  TOY, Kristopher ,  TANAMACHI, Dawn M.

IPC分类号： A61K39/00 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28

CPC分类号： C07K16/2803 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/6829 ,  A61K47/6849 ,  A61K51/1027 ,  A61K2039/505 ,  C07K16/3061 ,  C07K2317/21 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/70 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/92

摘要： The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.